China's over 100 billion pharmaceutical companies

As of the end of April, the 2021 performance of the four major pharmaceutical distribution giants, Sinopharm Holding, Shanghai Pharmaceuticals, China Resources Pharmaceuticals and Jiuzhoutong, have been disclosed

1.

1.

The performance of commercial companies and offline pharmacies in 2021 can be described as very different : the "big four" commercial companies will have an average revenue growth rate of 13.

The main reason for the above difference is that under the influence of the epidemic in 2020, the admission of patients was limited, and patients began to go to pharmacies to purchase drugs

From the perspective of revenue growth, the four major commercial revenue growth rates are around 14%, and the growth rate of China Resources Pharma is obvious.

Source: Company announcements, Zhongkang Industrial Research Center

2.

2.

Judging from the growth of net profit attributable to the parent, Shanghai Pharma and China Resources Pharma performed well

Figure 2 Net profit and growth of the four major pharmaceutical distributors in 2021 (unit: 100 million yuan)

Source: Company announcements, Zhongkang Industrial Research Center

3.

3.

Sinopharm Holding focuses more on the strategic layout of downstream retail pharmacies : by the end of 2021, Sinopharm Holding has 10,259 retail stores, an increase of 1,282 over the end of the previous year; 1,461 professional pharmacies, an increase of 144 over the previous year

Sinopharm focuses more on the strategic layout of downstream retail pharmacies

The strategy of Shanghai Pharmaceuticals can be summed up as "innovation" : it includes the introduction of tens of billions of funds from Yunnan Baiyao and the promotion of the reform of Shanghai Pharmaceuticals' system and mechanism

Shanghai Pharmaceuticals' strategy can be summed up as "innovation"

Compared with the first two distributors, the biggest highlight of China Resources Pharma is the branding of pharmaceutical manufacturing : it owns “999”, “Dong E E Jiao”, “Shuanghe”, “Jiangzhong”, “Zizhu”, etc.

Compared with the first two distributors, China Resources Pharma's biggest bright spot lies in the branding of pharmaceutical manufacturing

The highlights of Jointown are the "Wandian Alliance" plan and the "Power Health" platform : Relying on the advantages of supply chain and customer resources, Jointown integrates resources such as terminals, procurement, e-commerce, and information systems through the franchise model authorized by its Haoyaoshi retail brand.

The highlights of Jointown are the "Wandian Alliance" program and the "Power Health" platform

Summarize

Summarize

With the normalization of drug procurement and the advancement of DRG payment, the market-led drug pricing mechanism will gradually improve

In the context of the unified national market, the model of only relying on advance payment + distribution fee will eventually be integrated by industry leaders through mergers and acquisitions